New pharmacological treatments for improving renal outcomes in diabetes
- 4 May 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Nephrology
- Vol. 6 (6), 371-380
- https://doi.org/10.1038/nrneph.2010.57
Abstract
Diabetic nephropathy is the most common and most rapidly growing cause of end-stage renal failure in developed countries. Diabetic nephropathy results from complex interactions between genetic, metabolic and hemodynamic factors. Improvements in our understanding of the pathogenesis of fibrosis associated with diabetic kidney disease have led to the identification of several novel targets for the treatment of diabetic nephropathy. Albuminuria is a useful clinical marker of diabetic nephropathy, as it can be used to predict a decline in renal function. A reduction in albuminuria might not, however, be reflective of a protective effect of therapies focused on ameliorating renal fibrosis. Although new strategies for slowing down the progression of several types of renal disease have emerged, the challenge of arresting the relentless progression of diabetic nephropathy remains. In this Review, we discuss novel pharmacological approaches that aim to improve the renal outcomes of diabetic nephropathy, including the use of direct renin inhibitors and statins. We also discuss the promise of using antifibrotic agents to treat diabetic nephropathy. The need for novel biomarkers of diabetic nephropathy is also highlighted.Keywords
This publication has 131 references indexed in Scilit:
- Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis CAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2009
- Renal and Retinal Effects of Enalapril and Losartan in Type 1 DiabetesThe New England Journal of Medicine, 2009
- Rosuvastatin and Cardiovascular Events in Patients Undergoing HemodialysisThe New England Journal of Medicine, 2009
- Rhein reverses the diabetic phenotype of mesangial cells over‐expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathwayBritish Journal of Pharmacology, 2008
- Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activityExperimental Physiology, 2008
- NOX in liver fibrosisArchives of Biochemistry and Biophysics, 2007
- Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in db/db miceBiochemical and Biophysical Research Communications, 2003
- Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effectsKidney International, 2000
- Familial Clustering of Diabetic Kidney DiseaseThe New England Journal of Medicine, 1989
- Increased Plasma Inactive Renin in Diabetes MellitusThe New England Journal of Medicine, 1985